Acromegaly/complications/epidemiology; Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Body Mass Index; Child; Databases, Factual; Diabetes Complications/epidemiology; Disease Progression; Female; Follow-Up Studies; France/epidemiology; Human Growth Hormone/blood; Humans; Hypertension/complications/epidemiology; Insulin-Like Growth Factor I/analysis; Magnetic Resonance Imaging; Male; Middle Aged; Multivariate Analysis; Pituitary Neoplasms/complications/epidemiology; Registries; Risk Factors; Sex Ratio; Young Adult
Abstract :
[en] OBJECTIVES: The French Acromegaly Registry records data of acromegalic patients' since 1992 in French, Belgian (Liege), and Swiss (Lausanne) centers. We studied the prevalence of diabetes in this population looking for risk factors. Patients from one of the centers (Reims) were then analyzed more thoroughly. METHODS: This study has been conducted on all the patients recorded from 1999 until 2004 (519 patients). Evolution of cohorts' was reassessed in 2009. Of the different variables recorded in the registry: age, sex, body mass index (BMI), duration of acromegaly, GH, IGF1 and prolactin levels, pituitary tumor size, hormonal deficiencies, presence, duration and treatment of diabetes, hypertension, and rheumatological disease were analyzed. RESULTS: The prevalence of diabetes in the registry was 22.3%. Diabetic patients were older and had a higher BMI. Compared with the data of the French Social Security, acromegalic patients showed a more precocious apparition of diabetes and prevalence was higher in each age group. Compared with non-diabetic acromegalic subjects, diabetic patients had a more prolonged evolution of acromegaly before diagnosis. The levels of GH and IGF1 were not significantly different between the two groups. Only hypertension was significantly more frequent in diabetic patients. CONCLUSIONS: In our population, the prevalence of diabetes was estimated to be 22.3%. The GH and IGF1 levels did not appear as predictive factors for the presence of diabetes. On the contrary, age, BMI, and hypertension were significant risk factors as in the general population of type 2 diabetics.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Fieffe, Sandrine
Morange, Isabelle
PETROSSIANS, Patrick ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service d'endocrinologie clinique
Chanson, Philippe
Rohmer, Vincent
Cortet, Christine
Borson-Chazot, Francoise
Brue, Thierry
Delemer, Brigitte
Language :
English
Title :
Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry.
Melmed S. Medical progress: acromegaly. New England Journal of Medicine 2006 355 2558-2573. (doi:10.1056/NEJMra062453)
Colao A, Ferone D, Marzullo P & Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocrine Reviews 2004 25 102-152. (doi:10.1210/er.2002-0022)
Holdaway IM, Rajasoorya RC & Gamble GD. Factors influencing mortality in acromegaly. Journal of Clinical Endocrinology and Metabolism 2004 89 667-674. (doi:10.1210/jc.2003-031199)
Puder JJ, Nilavar S, Post KD & Freda PU. Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 2005 90 1972-1978. (doi:10.1210/jc.2004-2009)
Dekkers OM, Biermasz NR, Pereira AM, Romijn JA & Vandenbroucke JP. Mortality in acromegaly: a metaanalysis. Journal of Clinical Endocrinology and Metabolism 2008 93 61-67. (doi:10.1210/jc.2007-1191)
Møller N & Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocrine Reviews 2009 30 152-177. (doi:10.1210/er.2008-0027)
Jaffrain-Rea ML, Moroni C, Baldelli R, Battista C, Maffei P, Terzolo M, Correra M, Ghiggi MR, Ferretti E, Angeli A, Sicolo N, Trischitta V, Liuzzi A, Cassone R & Tamburrano G. Relationship between blood pressure and glucose tolerance in acromegaly. Clinical Endocrinology 2001 54 189-195. (doi:10.1046/j.1365-2265.2001.01206.x)
Jaffrain-Rea M, Minniti G, Moroni C, Esposito V, Ferretti E, Santoro A, Infusino T, Tamburrano G, Cantore G & Cassone R. Impact of successful transsphenoidal surgery on cardiovascular risk factors in acromegaly. European Journal of Endocrinology/European Federation of Endocrine Societies 2003 148 193-201. (Pubitemid 36305685)
Drange MR, Fram NR, Herman-Bonert V & Melmed S. Pituitary tumor registry: a novel clinical resource. Journal of Clinical Endocrinology and Metabolism 2000 85 168-174. (doi:10.1210/jc.85.1.168)
Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Werder KV & Melmed S. Criteria for cure of acromegaly: a consensus statement. Journal of Clinical Endocrinology and Metabolism 2000 85 526-529. (doi:10.1210/jc.85.2.526)
World health organization: Definition, diagnosis and classification of diabetes mellitus and its com- plications: Report of a WHO consultation. part 1: Diagnosis and classification of diabetes mellitus. Geneva, World Health Org. 1999.
Kusnik-Joinville O, Weill A, Salanave B, Ricordeau P & Allemand H. Prevalence and treatment of diabetes in france: trends between 2000 and 2005. Diabetes and Metabolism 2008 34 266-272. (doi:10.1016/j.diabet.2008.01.005)
Bringer J, Fontaine P, Detournay B, Nachit-Ouinekh F, Brami G & Eschwege E. Prevalence of diagnosed type 2 diabetes mellitus in the French general population: the INSTANT study. Diabetes and Metabolism 2009 35 25-31. (doi:10.1016/j.diabet.2008.06.004)
Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA & Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. Journal of Clinical Endocrinology and Metabolism 2006 91 4769-4775. (doi:10.1210/jc.2006-1668)
Alexander L, Appleton D, Hall R, Ross WM & Wilkinson R. Epidemiology of acromegaly in the newcastle region. Clinical Endocrinology 1980 12 71-79. (doi:10.1111/j.1365-2265.1980.tb03135.x)
Bengtsson BA, Edén S, Ernest I, Odén A & Sjögren B. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Medica Scandinavica 1988 223 327-335. (doi:10.1111/j.0954-6820.1988.tb15881.x)
Holdaway IM & Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999 2 29-41. (doi:10.1023/A:1009965803750)
Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, Gomez J-M, Halperin I, Lucas-Morante T, Moreno B, Obiols G, de Pablos P, Paramo C, Pico A, Torres E, Varela C, Vazquez J-A, Zamora J, Albareda M & Gilabert M. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish acromegaly registry (Registro Espanol De Acromegalia, Rea). European Journal of Endocrinology 2004 151 439-446. (doi:10.1530/eje.0.1510439)
Bex M, Abs R, T'Sjoen G, Mockel J, Velkeniers B, Muermans K & Maiter D. Acrobel-the belgian registry on acromegaly: a survey of the 'real-life' outcome in 418 acromegalic subjects. European Journal of Endocrinology 2007 157 399-409. (doi:10.1530/EJE-07-0358)
Wass JA, Cudworth AG, Bottazzo GF,Woodrow JC & Besser GM. An assessment of glucose intolerance in acromegaly and its response to medical treatment. Clinical Endocrinology 1980 12 53-59. (doi:10.1111/j.1365-2265.1980. tb03132.x)
Biering H, Knappe G, Gerl H & Lochs H. Prevalence of diabetes in acromegaly and cushing syndrome. Acta Medica Austriaca 2000 27 27-31. (doi:10.1046/j.1563-2571.2000.00106.x)
Møller N, Schmitz O, Jøorgensen JO, Astrup J, Bak JF, Christensen SE, Alberti KG & Weeke JO. Basal- and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. Journal of Clinical Endocrinology and Metabolism 1992 74 1012-1019. (doi:10.1210/jc.74.5.1012)
Dominici FP, Argentino DP, Muñoz MC, Miquet JG, Sotelo AI & Turyn D. Influence of the crosstalk between growth hormone and insulin signalling on the modulation of insulin sensitivity. Growth Hormone & IGF Research 2005 15 324-336. (doi:10.1016/j.ghir.2005.07.001)
Yakar S, Liu JL, Fernandez AM, Wu Y, Schally AV, Frystyk J, Chernausek SD, Mejia W & Le Roith D. Liver-specific IGF-1 gene deletion leads to muscle insulin insensitivity. Diabetes 2001 50 1110-1118. (doi:10.2337/diabetes.50.5. 1110)
Neggers SJ & van der Lely AJ. Modulation of glucocorticoid metabolism by the GH-IGF-I axis. Endocrine Development 2011 20 181-186. (doi:10.1159/000321243)
Ronchi C, Epaminonda P, Cappiello V, Beck-Peccoz P & Arosio M. Effects of two different somatostatin analogs on glucose tolerance in acromegaly. Journal of Endocrinological Investigation 2002 25 502-507. (Pubitemid 34661837)
Colao A, Auriemma RS, Galdiero M, Lombardi G & Pivonello R. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. Journal of Clinical Endocrinology and Metabolism 2009 94 3746-3756. (doi:10.1210/jc.2009-0941)
Colao A, Auriemma RS, Savastano S, Galdiero M, Grasso LF, Lombardi G & Pivonello R. Glucose tolerance and somatostatin analog treatment in acromegaly: a 12-month study. Journal of Clinical Endocrinology and Metabolism 2009 94 2907-2914. (doi:10.1210/jc.2008-2627)
Mazziotti G, Porcelli T, Bogazzi F, Bugari G, Cannavo S, Colao A, Cozzi R, De Marinis L, degli Uberti E, Grottoli S, Minuto F, Montini M, Spinello M & Giustina A. Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy. European Journal of Endocrinology 2011 164 341-347. (doi:10.1530/EJE-10-0811)
Kinoshita Y, Fujii H, Takeshita A, Taguchi M, Megumi M, Oyama K, Yamada S & Takeuchi Y. Impaired glucose metabolism in Japanese patients with acromegaly is restored after successful pituitary surgery if pancreatic {beta}-cell function is preserved. European Journal of Endocrinology 2011 164 467-473. (doi:10. 1530/EJE-10-1096)
Colao A, Auriemma RS, Galdiero M, Cappabianca P, Cavallo LM, Esposito F, Grasso LF, Lombardi G & Pivonello R. Impact of somatostatin analogs vs surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study. Journal of Clinical Endocrinology and Metabolism 2009 94 528-537. (doi:10.1210/jc.2008-1546)
Gordon DA, Hill FM & Ezrin C. Acromegaly: a review of 100 cases. Canadian Medical Association Journal 1962 87 1106-1109.
Vitale G, Pivonello R, Auriemma RS, Guerra E, Milone F, Savastano S, Lombardi G & Colao A. Hypertension in acromegaly and in the normal population: prevalence and determinants. Clinical Endocrinology 2005 63 470-476. (doi:10.1111/j.1365-2265.2005.02370.x)
